多发性骨髓瘤中的单克隆抗体：当前和新兴的靶点及作用机制。
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
机构信息
Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Division of Hematology and Research Unit in Translational Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
出版信息
Best Pract Res Clin Haematol. 2020 Mar;33(1):101143. doi: 10.1016/j.beha.2020.101143. Epub 2020 Jan 11.
The recent development of monoclonal antibodies (mAbs) has revolutionized the treatment armamentarium for multiple myeloma. The success of daratumumab and elotuzumab in relapsed/refractory patients, has generated tremendous enthusiasm for mAbs in this disease. Combination treatment with other anti-myeloma treatment modalities and clinical evaluation in newly diagnosed patients are expected to fundamentally change the natural history of the disease. Advances in biopharmaceutical engineering together with a robust interest in novel mAb-derivatives, including antibody drug conjugates and poly-specific antibodies are the next rapidly approaching treatment frontier in multiple myeloma. In this review, we comprehensively outline the currently available evidence and the future landscape of mAbs and mAb-derivative therapies in multiple myeloma.
单克隆抗体（mAbs）的最新发展彻底改变了多发性骨髓瘤的治疗手段。达雷妥尤单抗和埃罗妥珠单抗在复发/难治性患者中的成功，为该疾病中的 mAbs 带来了巨大的热情。与其他抗骨髓瘤治疗方式联合治疗以及在新诊断患者中的临床评估有望从根本上改变疾病的自然病程。生物制药工程的进步以及对新型 mAb 衍生物（包括抗体药物偶联物和多特异性抗体）的浓厚兴趣，是多发性骨髓瘤治疗的下一个快速发展前沿。在这篇综述中，我们全面概述了目前 mAbs 和 mAb 衍生物治疗多发性骨髓瘤的现有证据和未来前景。
Zotero 插件